• where experts go to learn about FDA
  • Year: 2013

    • Real-World Implications of United States v. Caronia – A Hyman, Phelps & McNamara, P.C. WebinarJanuary 10th, 2013

      Hyman, Phelps & McNamara, P.C. will hold a complimentary webinar on Thursday, January 31, 2013, from 12:00 – 2:00 PM (Eastern) on the Second Circuit's recent and long-awaited decision in United States v. Caronia.  This webinar is not just another summary of the Second Circuit's decision. Nor …

    • When is 5-Year NCE Exclusivity Less Than 5 Years?January 9th, 2013

      By Kurt R. Karst –       Every once in a while we receive a series of similar questions from various quarters such that a critical mass has been reached justifying a blog post on the topic.  This is one of those posts.  And it has to do …

    • A Pre-MMA 180-Day Exclusivity Punt? What Gives?January 8th, 2013

      By Kurt R. Karst – Although the number of cases involving 180-day exclusivity under the version of the FDC Act in effect before the December 8, 2003 enactment of the Medicare Modernization Act (“MMA”) is nearing an end, the pre-MMA statute, and the handling of it …

    • FDA Ramps Up Focus on Advertising of Restricted Devices to ConsumersJanuary 7th, 2013

      By Jeffrey K. Shapiro – FDA has enhanced authority over the sale, distribution and use of devices that the agency designates as “restricted.”  21 U.S.C. § 360j(e).  FDA almost always designates Class III devices as “restricted devices” in premarket application (“PMA”) approval orders.  21 U.S.C. …

    • On FSMA’s Second Anniversary, FDA Releases Two Major Proposed RulesJanuary 6th, 2013

      By Ricardo Carvajal – FDA released two long-awaited proposed rules to implement key provisions of the Food Safety Modernization Act ("FSMA"): Current Good Manufacturing Practice and Hazard Analysis and Risk-Based Preventive Controls for Human Food and Standards for the Growing, Harvesting, Packing, and Holding of Produce …

    • CDRH Releases Three Final Guidance DocumentsJanuary 3rd, 2013

      By Jennifer D. Newberger – On December 31, 2012, CDRH released three final guidance documents, the drafts of which were issued in the summer and fall of 2012.  The quick finalization of these guidance documents is likely due to their fairly uncontroversial nature, since they are …

    • FDA and Ranbaxy Prevail in Dispute Over Generic DIOVAN 180-Day Exclusivity; Court Grants Motions for Summary JudgmentJanuary 2nd, 2013

      By Kurt R. Karst –       Last week in a post-Christmas decision, Judge John D. Bates of the U.S. District Court for the District of Columbia granted both FDA’s and Intervenor-Defendant Ranbaxy Laboratories Limited’s (“Ranbaxy’s”) Motions for Summary Judgment and denied Mylan Laboratories Limited’s and Mylan …

    • The Prosecution of Gary D. Osborn—An Old School “Park” Prosecution?January 1st, 2013

      By John R. Fleder – We have extensively written about the “Park Doctrine” (see, e.g., here and here)  In United States v. Park, 421 U.S. 658 (1975), the Supreme Court authorized the government to criminally prosecute individuals for violations of the FDCA even if a corporate …